Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
COVID-19 among patients with multiple sclerosis: a systematic review
M Barzegar, O Mirmosayyeb… - Neurology …, 2021 - AAN Enterprises
Objective We systematically reviewed the literature on COVID-19 in patients with multiple
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …
Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis
MP Sormani, N De Rossi, I Schiavetti… - Annals of …, 2021 - Wiley Online Library
Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis
A Salter, RJ Fox, SD Newsome, J Halper… - JAMA …, 2021 - jamanetwork.com
Importance Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather
information on clinical outcomes and risk factors associated with morbidity and mortality in …
information on clinical outcomes and risk factors associated with morbidity and mortality in …
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis
S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke… - Neurology, 2021 - AAN Enterprises
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …
[HTML][HTML] COVID-19 in ocrelizumab-treated people with multiple sclerosis
R Hughes, L Whitley, K Fitovski, HM Schneble… - Multiple sclerosis and …, 2021 - Elsevier
Background There are limited data on the impact of coronavirus disease 2019 (COVID-19)
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people …
Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity
S Simpson-Yap, A Pirmani, T Kalincik… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Certain demographic and clinical characteristics, including the
use of some disease-modifying therapies (DMTs), are associated with severe acute …
use of some disease-modifying therapies (DMTs), are associated with severe acute …
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: an international consensus statement
In this consensus statement, we provide updated recommendations on multiple sclerosis
(MS) management during the COVID-19 crisis and the post-pandemic period applicable to …
(MS) management during the COVID-19 crisis and the post-pandemic period applicable to …
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM
Background There is no data regarding COVID-19 in Multiple Sclerosis (MS) and
neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America. Objective The …
neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America. Objective The …
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry
T Spelman, L Forsberg, K McKay… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: The primary objective of this study was to analyse the association between
multiple sclerosis (MS) disease-modifying therapy (DMT) exposure and hospitalisation in …
multiple sclerosis (MS) disease-modifying therapy (DMT) exposure and hospitalisation in …